Literature DB >> 9527115

Economic implications of chronic sinusitis.

R E Gliklich1, R Metson.   

Abstract

An approach to cost analysis useful in understanding the economic implications of surgical intervention on chronic sinusitis is break-even time analysis. The break-even time is the time until cost savings associated with improved health status after surgery equal the up-front costs of the operation itself. Data from 100 consecutive patients undergoing sinus operation were obtained by survey before surgery and at quarterly intervals for 1 year with statistically validated outcome measures (Medical Outcome Study Short Form 36-Item Health Survey, Chronic Sinusitis Survey). Direct and indirect costs were obtained or derived for this cohort. The cost of sinus medications, including over-the-counter remedies, nasal steroid sprays, and antibiotics, averaged $1220 per patient per year before surgery and $629 after surgery (p < 0.0001), which is a 48% reduction. Surgical costs averaged $6490 per patient. Economic modeling predicted a break-even time of approximately 7 years assuming a 3% surgical revision rate per year, a 3% decrease in sickness-related disability, and a 5% discount rate. The model was sensitive to changes in the total cost of operation, the surgical revision rate, and the anticipated disability benefit. We conclude that significant direct and indirect medical cost savings may be achieved after surgical intervention for chronic sinusitis and these savings eventually break even with the total cost of surgery itself.

Entities:  

Mesh:

Year:  1998        PMID: 9527115     DOI: 10.1016/S0194-59989870313-4

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   5.591


  15 in total

1.  [Rhinosinusitis guidelines--unabridged version: S2 guidelines from the German Society of Otorhinolaryngology, Head and Neck Surgery].

Authors:  B A Stuck; C Bachert; P Federspil; W Hosemann; L Klimek; R Mösges; O Pfaar; C Rudack; H Sitter; M Wagenmann; R Weber; K Hörmann
Journal:  HNO       Date:  2012-02       Impact factor: 1.284

Review 2.  Comprehensive review on endonasal endoscopic sinus surgery.

Authors:  Rainer K Weber; Werner Hosemann
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2015-12-22

3.  Examination of high-antibiotic users in a multi-institutional cohort of chronic rhinosinusitis patients.

Authors:  Vijay R Ramakrishnan; Jess C Mace; Zachary M Soler; Timothy L Smith
Journal:  Int Forum Allergy Rhinol       Date:  2017-01-13       Impact factor: 3.858

4.  Topographic gene expression in the sinonasal cavity of patients with chronic sinusitis with polyps.

Authors:  Michael P Platt; Zachary M Soler; Shyan-Yuan Kao; Ralph Metson; Konstantina M Stankovic
Journal:  Otolaryngol Head Neck Surg       Date:  2011-07       Impact factor: 3.497

5.  Saline irrigation spells relief for sinusitis sufferers.

Authors:  Mari Egan; John Hickner
Journal:  J Fam Pract       Date:  2009-01       Impact factor: 0.493

6.  [Chronic rhinosinusitis. Subjective assessment of benefit 1 year after functional endonasal sinus surgery].

Authors:  I Baumann; G Blumenstock; C Klingmann; M Praetorius; P K Plinkert
Journal:  HNO       Date:  2007-11       Impact factor: 1.284

7.  Cost effectiveness of nasal budesonide versus surgical treatment for nasal polyps.

Authors:  Fredrik Berggren; Leif Johansson
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

8.  Endoscopic sinus surgery reduces antibiotic utilization in rhinosinusitis.

Authors:  Naveen D Bhandarkar; Jess C Mace; Timothy L Smith
Journal:  Int Forum Allergy Rhinol       Date:  2011 Jan-Feb       Impact factor: 3.858

Review 9.  [Validated instruments to measure quality of life in patients with chronic rhinosinusitis].

Authors:  I Baumann
Journal:  HNO       Date:  2009-09       Impact factor: 1.284

10.  Regional variations in chronic rhinosinusitis, 2003-2006.

Authors:  Wendy M Smith; Terence M Davidson; Claire Murphy
Journal:  Otolaryngol Head Neck Surg       Date:  2009-09       Impact factor: 3.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.